Themis Bioscience GmbH has announced the closing of a EUR 5 Million Series A Financing round co-led by the international venture capital funds Ventech and Crédit Agricole Private Equity.
The investment will be used to expedite the pre-clinical and clinical development activities for Themis’ lead product candidates, a Dengue and a Chikungunya Fever vaccine.
Both vaccine candidates have demonstrated promising preclinical data. They are based on a novel vaccine vector technology that was initially developed at the Institut Pasteur in Paris, with which Themis collaborates.
“We are delighted to welcome Ventech and Crédit Agricole as investors in our company. This investment will allow us to move our development projects forward at full speed and to demonstrate clinical proof-of-concept”, states Erich Tauber, CEO of Themis Bioscience.
“We are convinced that Themis and its technology platform have great potential to deliver very promising vaccine candidates that will already at early clinical stage put the company into an ideal position to become an attractive licensing partner for major pharmaceutical companies”, commented Karl Naegler, General Partner at Ventech.
Naegler continued, “Themis is to develop a new generation of vaccines for emerging diseases, based on a highly promising technology and an experienced core team” adds Bruno Montanari, Director at Crédit Agricole Private Equity’s Venture Capital team.
Themis Bioscience was founded in Vienna in 2009 and received seed financing by the academic business incubator INiTS, the austria wirtschaftsservice (aws) and The Austrian Research Promotion Agency (FFG).